Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This refers to a comparative clinical study conducted by The Maas Clinic evaluating two distinct botulinum toxin type A products: Botox Cosmetic (onabotulinumtoxinA) and Dysport (abobotulinumtoxinA). Both are biologic neuromodulators used for the temporary improvement in the appearance of moderate to severe lateral orbital rhytids (crow's feet). They share a common mechanism of action: the heavy chain of the toxin binds to neuronal surfaces, while the light chain acts as a zinc-dependent endopeptidase that cleaves SNAP-25 (Synaptosomal-associated protein 25). This cleavage prevents the formation of the SNARE complex, thereby blocking the release of the neurotransmitter acetylcholine at the neuromuscular junction, leading to localized muscle relaxation. The Maas Clinic study was a randomized, double-blind, split-face Phase 4 trial designed to compare the efficacy, onset, and duration of these two specific formulations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Botox Cosmetic or Dysport-The Maas Clinic-lateral orbital rhytids.